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Manuscript Invited Editorial
Commentary 
 
The upcoming UN high-level meeting on universal health coverage in September provides a 
developmental framework for international and national agendas on the universal prevention 
and treatment packages and financial protection, worldwide. [1, 2] Universal coverage of 
prevention and treatment of chronic diseases is a very relevant topic area given the globally 
rising non-communicable disease epidemics in the world’s ageing populations.[3-8] In 
addition, there is increasing recognition of the late chronic consequences of major infections 
exemplified by post-TB lung damage, metabolic consequences in HIV, neuropathologies 
from meningitis and malaria, and chronic morbidity from neglected tropical diseases, like in 
lymphatic filariasis. These developments demand a shifts towards the development and 
stepped-up provision of new and integrated models of chronic care provision, especially in 
low- and middle-income settings. [7] Positive evidence for fixed-dose treatment 
combinations (FDCs) is accumulating, along with affordable strategies to improved access to, 
and use of, effective medical prevention and treatment, especially in chronic conditions. [4-6, 
9-13] FDCs have important advantages for patients and health systems, including simpler 
dose schedules, decreased pill burden, reduced stockouts, easier task sharing, training, and 
supervision, resulting in promoting large-scale access, acceptance, and production, such as 
reported in this issue and as also seen in HIV and TB control. [9, 10] 
   
Lung et al. [10] report the attractiveness in both health benefits and economic terms of triple 
fix-dose combinations (FDCs) in the treatment of high blood pressure, combining 
amlodipine, telmisartan and chlorthalidone.  FDCs, which combine two or more BP lowering 
drugs that are commonly taken together into a single pill, have been proven to improve 
patients’ adherence to medication regimens and BP control rates in a Sri Lankan trial, while 
their scenarios show the attractiveness in terms of health care costs and life years gained and 
disability prevented.  
Consequently, in an unusually rapid reaction, the World Health Organization has recently 
added FDCs of blood pressure lowering drugs to its Essential Medicines List, supported by 
relevant societal and professional organisations. It is a shining example of international co-
ordination and collaboration. Adding the combination of BP lowering drugs to the list is 
essential to improve the availability and affordability of these drugs. It promotes access for 
over 1 billion people with high BP worldwide to regularly take medication to prevent strokes 
and myocardial infarctions resulting in mid-aged disability and premature death.[14]  
 Inevitably, the economic study by Lung et al. [10] is based on limited empirical observations 
and during only two years  while the differences with control cases show a plateau after six 
weeks.  Their TRIUMPH trial cannot be considered as a pure ‘efficacy’ trial.  In real-life 
settings as it the case one can expect short-term compliance and Hawthorne effects, while in 
the long-term economic evaluation changes in long-term behaviour and compliance are 
important. [10] In addition, non-linearity of the risk functions, depending on absolute BP 
levels, age, and selective survival effects may result in huge differences in outcomes between 
sub-populations.  
Li et al.[9] take the FDCs one step further and show the potential health effect and cost 
reductions of the large-scale introduction of FDCs including aspirin, lisinopril, atenolol, and 
simvastatin to address multiple risk factors,. Their careful and well-documented model-based 
economic analyses one more attempt to assess the options for secondary CVD risk prevention 
in large country populations across the world. They recommend a large-scale introduction of 
this 'polypill' for secondary prevention. There is one caveat: aspirin in primary CVD 
prevention was recently shown to be ineffective [15]). Secondary prevention in polypill trials 
show improvements in proxy outcomes, but not in mortality outcomes, possibly due to lack 
of sample size / follow-up duration. Primary and secondary CVD prevention has been 
addressed as early as Murray [12], including the potential benefits of polypill combinations. 
[8] 
Other treatment combinations are already in use in the treatment of chronic conditions 
including lung health [3, 4, 6], diabetes ([5], HIV and tuberculosis [7, 11]. In lung health 
there is the question if a simple strategy of using a combined corticosteroid/rapid-onset long-
acting ß2 agonist (ICS/LABA) inhaler ‘as required’ or, if clinically indicated, ‘both as 
required, and regularly’ reduce asthma exacerbations in children and adults LMIC settings, 
with a possible potential role in the management of post-TB chronic lung disease. [4, 6].  . 
 
Rigorous epidemiological and economic evaluation of FDCs is complex: mono-therapeutic 
strategies, in many cases, are the norm and widely accepted in health guidelines and in 
clinical practise. Both limited effectiveness information and ethical boundaries in the 
identification of control groups make the use of mathematical modelling unavoidable. [16, 
17]   In a state-of-the-art approach, Li et al.[9]  use estimates from the PURE study, including 
compliance, as a control. They use the proxy outcomes of a single LMIC trial and the 
aggregated compliance data from two HIC trials, calibrated against recent BOD estimates. 
They optimistically include the health effects of the four individual drugs secondary event 
prevention among post-first-event patients. These combined, multiplicative, indeed proxy 
effects of their 'polypill' are simulated in scenarios to estimate the potential population 
benefits. It is realistic to weight the benefits against both the health care cost based on 
international generic pricing and local commercial pricing. However, the assumed potential 
cost-offsets from preventing secondary events will be low, in many resource-limited settings. 
Hopefully, in the near future monitoring the implementation of up-scaling efforts will teach 
us on the real-life effectiveness of these FDCs.  
 
Findings from economic evaluations - cost-effectiveness estimates – often stimulate debates 
on what level of outcomes is economically attractive. The WHO CHOICE programme has 
modified its position substantially [16], following the 2
nd
 Panel on Cost-effectiveness. They 
conclude that there is no absolute (WHO) cost-effectiveness threshold and individual 
countries should define their own approach [17].  The UK, through the threshold of £20,000 
per healthy year gained set by NICE, is the only country that applies an absolute standard in 
decision making on package formulations. The best approach globally is to respect national 
governmental decision-making that can take into account country standards and the country 
overall situation and the particulars of the health system.[16-19] It is striking that Lung’s 
group of clinical authors is based in California, with few members from India, Mexico, and 
Nigeria, and none from China. This calls into question their ability to address affordability, 
national opportunity costs (total budget impact), feasibility, and generalisability at country 
and sub-country levels. One would like to see an earlier involvement of funding bodies, both 
internationally and nationally. 
 
Real life policy making in low-income settings is complex and will increase in complexity as 
more and more options become available to deal with the health burden of chronic 
conditions. Although cost-effective, the overall national budget impacts, especially in the 
larger countries, of most new intervention packages can nevertheless be huge, as the number 
of people with chronic conditions is ever increasing.  Assuming concurrent retail market 
pharmaceutical prices, these budgets may be at 10% of the per capita GDP. These are huge 
budgets in large economies. Would Ministries of Health and Finance or national cabinets 
prefer to use this money in a different way in health or otherwise?  Inevitably, the ongoing 
equity debates in allocation of country resources have been part of national decision making 
for decades, especially in the case of LMICs. It is striking, that the UN SDGs leading theme 
is the inequalities between population sub-groups, including gender, the poor, the disabled, 
and minorities but also the huge inequalities between countries. These equity questions have 
not been clearly addressed in the two studies, nor in most other recent evaluations.  Certainly, 
from now on, progressive realisation i.e. the promotion of equity in universal access and 
coverage will be higher on the agenda, given proven effectiveness and efficiency of new 
interventions and strategies. [1, 2, 18-20] 
 
Existing recommendations in relation to the upcoming high-level UN meeting focus on 
political leadership beyond health, to exclude leave no one behind, to regulate and legislate,  
internationally and nationally the upcoming UHC efforts, while upholding quality of 
(chronic) care [1]. Universal coverage of prevention and treatment of chronic conditions will 
have to be a substantial part of this process, while at the same time reducing inequalities in 
financing, access and utilization, in between countries and within countries. [18-20] 
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